

SECRETARY'S REPORT



The first Excom meeting of 2005 delivered the pleasure of the return of Matt Haus from China – welcome back, Matt!

This year promises to be a very active one for allergy in SA. Watch the ALLSA website for exciting developments involving our journal, *Current Allergy & Clinical Immunology*. Please support our journal by submitting articles, case reports and letters. The November 2004 edition of the journal focused on tuberculosis and introduced new authors to our readers. Well done to the editors and Gerhard Walzl on an excellent issue!

Durban will be the centre of South African allergy this year: the diploma exam will be held there in May and the congress in August (26-28). The congress programme looks very interesting, with a major emphasis on asthma and with outstanding international as well as local speakers. We know the Elangeni and Ahmed

Manjra combination always provides for excellence – this year promises to be no different!

Gauteng has also not been asleep: two intercity meetings have stimulated tremendous interest. Well done to André van Niekerk and Andrew Halkas. The annual Allergy Update will also be in Johannesburg in May – see details elsewhere in this issue.

July 6 has been proclaimed World Allergy Day and ALLSA will promote allergy awareness in South Africa. Please make a note of this date and indicate if you wish to do something in your practice.

We look forward to meeting all our ALLSA friends at the Durban congress – please register now!

Sharon Kling

Secretary

PRODUCT NEWS

INTRODUCING DUOLIN

Cipla Medpro markets one of the most extensive respiratory ranges in South Africa. Introduction of the CFC-free products, Budeflam HFA and Asthavent Eco, well within the Montreal Protocol deadline demonstrates our commitment to 'preserving the planet'.

The combined effects of ageing, cigarette smoking and environmental pollution contribute to an increasing incidence of COPD. One of the key therapeutic options is bronchodilator therapy, with nebulisation being the most effective.

Cipla Medpro provides another highly cost-effective treatment for COPD, this time in the form of **Duolin Respules**. This first to market generic combines ipratropium (0.5 mg) with salbutamol (2.5 mg) in a 2.5 ml respule (UDV). Duolin is indicated for the treatment of reversible bronchospasm.

Duolin, packed in 60s, has an SEP of R241.00 (excl VAT). This provides a 40% saving compared to the originator which has an SEP of R362.82 (excl VAT).

Can you afford not to use our 'relieving solution' for the lungs and your patient's pockets?

For more information, please contact Anton Fourie at 021-914-0520 or e-mail anton@ciplamedpro.co.za

REFERENCE

1. PCD 31 JAN 2005
Duolin S3 Reg No.37/10.2.1/0012

